Cutibacterium avidum GENSC01 Strain for Atopic Dermatitis Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for atopic dermatitis and inflammatory skin diseases are inadequate, as they fail to effectively address the proliferation of Staphylococcus aureus and the resulting skin barrier dysfunction, leading to chronic inflammation and disease progression.

Innovation Solution

A novel strain of Cutibacterium avidum, specifically the GENSC01 strain, and its culture are used in combination with rosmarinic acid to inhibit the growth and biofilm formation of Staphylococcus aureus, improving skin symptoms and enhancing skin moisturization and barrier function.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for atopic dermatitis, then skin inflammation is temporarily suppressed, but the proliferation of S. aureus continues and skin barrier function remains impaired

Engineering Contradiction:

Improveefficacy of treatmentVSAvoidS. aureus proliferation

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent utilizes the bacteriocin-producing capability of Cutibacterium avidum GENSC01 to convert a potentially harmful bacterium into a therapeutic agent. The bacteriocin produced by this strain specifically inhibits S. aureus growth, transforming the treatment approach from suppressing symptoms to actively eliminating the pathogenic bacteria causing the disease

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent introduces Cutibacterium avidum GENSC01 as an intermediary organism that mediates the treatment of atopic dermatitis. This bacterium produces bacteriocin which acts as a natural antibiotic, providing anti-S. aureus activity without the need for conventional synthetic antibiotics, thereby addressing both inflammation and bacterial proliferation

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-generated harmful factors

If antibiotics are used to inhibit S. aureus proliferation, then bacterial growth is suppressed, but skin barrier function and moisturization are not improved

Engineering Contradiction:

ImproveS. aureus growth inhibitionVSAvoidskin barrier function

Core Design Contradiction:

Object-generated harmful factorsVSReliability

Solution Approach 1:

The patent employs Cutibacterium avidum GENSC01 as a multi-functional therapeutic agent that simultaneously provides three benefits: (1) produces bacteriocin to inhibit S. aureus growth, (2) reduces inflammation through cytokine modulation, and (3) improves skin barrier function and moisturization. This single strain addresses multiple aspects of atopic dermatitis that previously required separate treatments

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Object-affected harmful factors

If inflammation-inducing cytokines are suppressed, then skin inflammation is reduced, but the underlying cause involving S. aureus and skin barrier dysfunction is not addressed

Engineering Contradiction:

Improveinflammation responseVSAvoidskin barrier dysfunction

Core Design Contradiction:

Object-affected harmful factorsVSObject-generated harmful factors

Solution Approach 1:

The patent takes preliminary action by introducing Cutibacterium avidum GENSC01 that proactively addresses the root causes of atopic dermatitis before inflammation fully develops. The bacterium's bacteriocin prevents S. aureus colonization, and its metabolic products preemptively strengthen skin barrier function, preventing the inflammatory cascade from initiating

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The Cutibacterium avidum GENSC01 strain and its culture demonstrate antibacterial activity against Staphylococcus aureus, inhibit biofilm formation, and improve skin moisturization, effectively treating atopic dermatitis and inflammatory skin diseases while reducing inflammation and odor, providing a novel approach to managing these conditions.

Implementation Method 1

The Cutibacterium avidum GENSC01 strain or its culture may show an antibacterial activity against Staphylococcus aureus or Cutibacterium acnes

Methodology Applied

Scientific EffectAntibacterial activity:

Implementation Method 2

it may have an activity of removal or formation-inhibiting of biofilm which is produced by the S. aureus

Methodology Applied

Scientific EffectBiofilm formation inhibition:

Implementation Method 3

the fermented filtrate of the strain may have an effect of facilitating the expression of filaggrin and claudin-1

Methodology Applied

Scientific EffectGene expression enhancement:

Data Source

PatentUS11478513B2Cutibacterium avidum strain, and composition for preventing or treating atopic dermatitis, comprising strain or cultured product thereof

Publication Date: 2022.10.25 GENOME & CO INC

AI summary

The present invention relates to Cutibacterium avidum GENSC01 strain (KCTC 13596BP). The present invention also relates to a composition comprising the strain or its culture, and use thereof. The present invention is effective in improvement, prevention or treatment of atopic dermatitis, acne or skin inflammation by fine dust.